Under the agreement, the prices of Ozempic and Wegovy from Novo Nordisk will decline from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx.

Employer costs for GLP-1 agonists and similar drugs could end up averaging $3.17 to $22.88 per enrollee per month.

A class-action lawsuit was filed last week against CVS Caremark in the Southern District of New York over its decision to replace Eli Lilly’s popular GLP-1 weight-loss drug Zepbound with Wegovy from Novo Nordisk.

About 12% of all U.S. adults have already tried using GLP-1 agonist drugs to control their weight, according to a survey report by three researchers at RAND.